AT 982

Drug Profile

AT 982

Alternative Names: AT-002 - Audentes Therapeutics; AT982

Latest Information Update: 01 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Audentes Therapeutics
  • Class Gene therapies
  • Mechanism of Action Alpha glucosidase expression stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glycogen storage disease type II

Most Recent Events

  • 09 May 2018 Audentes Therapeutics plans to file an IND application, for systemic AT 982 for Glycogen storage disease type II, in the fourth quarter of 2018
  • 09 May 2018 Audentes plans a phase I/II proof of concept trial for Glycogen storage disease type II in the first half of 2019
  • 31 Aug 2017 AT 982 is still in preclinical trials for Glycogen storage disease type II in USA (Parenteral/Systemic) (Audentes Therapeutics pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top